JP6513949B2 - Ｖｄｊ組み換え産物を特定する方法 - Google Patents
Ｖｄｊ組み換え産物を特定する方法 Download PDFInfo
- Publication number
- JP6513949B2 JP6513949B2 JP2014559299A JP2014559299A JP6513949B2 JP 6513949 B2 JP6513949 B2 JP 6513949B2 JP 2014559299 A JP2014559299 A JP 2014559299A JP 2014559299 A JP2014559299 A JP 2014559299A JP 6513949 B2 JP6513949 B2 JP 6513949B2
- Authority
- JP
- Japan
- Prior art keywords
- vdj
- cell population
- recombinant
- product
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000006798 recombination Effects 0.000 title claims description 94
- 238000005215 recombination Methods 0.000 title claims description 93
- 238000000034 method Methods 0.000 claims description 118
- 210000004027 cell Anatomy 0.000 claims description 85
- 108020004414 DNA Proteins 0.000 claims description 76
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 75
- 238000006243 chemical reaction Methods 0.000 claims description 69
- 239000012634 fragment Substances 0.000 claims description 54
- 108091034117 Oligonucleotide Proteins 0.000 claims description 43
- 108091008146 restriction endonucleases Proteins 0.000 claims description 39
- 229960002685 biotin Drugs 0.000 claims description 38
- 235000020958 biotin Nutrition 0.000 claims description 38
- 239000011616 biotin Substances 0.000 claims description 38
- 238000012163 sequencing technique Methods 0.000 claims description 34
- 101150008942 J gene Proteins 0.000 claims description 33
- 101150117115 V gene Proteins 0.000 claims description 26
- 108010090804 Streptavidin Proteins 0.000 claims description 19
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 15
- 238000011144 upstream manufacturing Methods 0.000 claims description 15
- 108091008874 T cell receptors Proteins 0.000 claims description 14
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 14
- 238000000527 sonication Methods 0.000 claims description 14
- 108060003951 Immunoglobulin Proteins 0.000 claims description 12
- 210000005260 human cell Anatomy 0.000 claims description 12
- 102000018358 immunoglobulin Human genes 0.000 claims description 12
- 108020004511 Recombinant DNA Proteins 0.000 claims description 10
- 238000012545 processing Methods 0.000 claims description 8
- 238000010008 shearing Methods 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 4
- 230000016784 immunoglobulin production Effects 0.000 claims description 3
- 239000000047 product Substances 0.000 description 98
- 239000000523 sample Substances 0.000 description 73
- 239000011324 bead Substances 0.000 description 49
- 108090000623 proteins and genes Proteins 0.000 description 49
- 239000000203 mixture Substances 0.000 description 45
- 108020004707 nucleic acids Proteins 0.000 description 41
- 102000039446 nucleic acids Human genes 0.000 description 41
- 150000007523 nucleic acids Chemical class 0.000 description 41
- 239000000872 buffer Substances 0.000 description 36
- 241000699666 Mus <mouse, genus> Species 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 25
- 239000006228 supernatant Substances 0.000 description 23
- 239000002299 complementary DNA Substances 0.000 description 15
- 101100310856 Drosophila melanogaster spri gene Proteins 0.000 description 13
- 238000001847 surface plasmon resonance imaging Methods 0.000 description 13
- 238000000137 annealing Methods 0.000 description 12
- 210000003719 b-lymphocyte Anatomy 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 238000009396 hybridization Methods 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 208000029462 Immunodeficiency disease Diseases 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 230000003321 amplification Effects 0.000 description 8
- 238000003199 nucleic acid amplification method Methods 0.000 description 8
- 230000029087 digestion Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000008707 rearrangement Effects 0.000 description 7
- 108091081021 Sense strand Proteins 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 102000006306 Antigen Receptors Human genes 0.000 description 5
- 108010083359 Antigen Receptors Proteins 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 229920000136 polysorbate Polymers 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 4
- 102000012410 DNA Ligases Human genes 0.000 description 4
- 108010061982 DNA Ligases Proteins 0.000 description 4
- 239000000074 antisense oligonucleotide Substances 0.000 description 4
- 238000012230 antisense oligonucleotides Methods 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 2
- 102100039352 Immunoglobulin heavy constant mu Human genes 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010001244 Tli polymerase Proteins 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000001823 molecular biology technique Methods 0.000 description 2
- 238000007481 next generation sequencing Methods 0.000 description 2
- 239000007793 ph indicator Substances 0.000 description 2
- 238000002702 ribosome display Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000004291 sulphur dioxide Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 1
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102100039564 Leukosialin Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 101100043638 Solanum tuberosum SS3 gene Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000007720 allelic exclusion Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001615 biotins Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000002196 fr. b Anatomy 0.000 description 1
- 210000000540 fraction c Anatomy 0.000 description 1
- 210000003297 immature b lymphocyte Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000005257 nucleotidylation Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1203720.6A GB201203720D0 (en) | 2012-03-02 | 2012-03-02 | Method of identifying VDJ recombination products |
| GB1203720.6 | 2012-03-02 | ||
| PCT/GB2013/050516 WO2013128204A1 (en) | 2012-03-02 | 2013-03-01 | Method of identifying vdj recombination products |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015509724A JP2015509724A (ja) | 2015-04-02 |
| JP2015509724A5 JP2015509724A5 (enExample) | 2016-04-14 |
| JP6513949B2 true JP6513949B2 (ja) | 2019-05-22 |
Family
ID=46003032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014559299A Expired - Fee Related JP6513949B2 (ja) | 2012-03-02 | 2013-03-01 | Ｖｄｊ組み換え産物を特定する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9797014B2 (enExample) |
| EP (1) | EP2820153B1 (enExample) |
| JP (1) | JP6513949B2 (enExample) |
| GB (1) | GB201203720D0 (enExample) |
| WO (1) | WO2013128204A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3063295B1 (en) | 2013-10-29 | 2017-12-13 | Region Syddanmark | Method for analyzing body fluid samples |
| US12043856B2 (en) | 2016-05-24 | 2024-07-23 | The Translational Genomics Research Institute | Molecular tagging methods and sequencing libraries |
| US11674137B2 (en) * | 2016-05-27 | 2023-06-13 | Haplox Biotechnology (Shenzhen) Co., Ltd. | Adaptor for sequencing DNA at ultratrace level and use thereof |
| ES2977787T3 (es) * | 2017-01-31 | 2024-08-30 | Ludwig Inst For Cancer Res Ltd | Métodos mejorados de secuenciación de receptores de células inmunitarias |
| US20200131564A1 (en) * | 2017-07-07 | 2020-04-30 | Board Of Regents, The University Of Texas System | High-coverage and ultra-accurate immune repertoire sequencing using molecular identifiers |
| EP3695010A4 (en) * | 2017-10-10 | 2021-11-17 | Memorial Sloan-Kettering Cancer Center | PRIMER EXTRACTION AND CLONALITY DETECTION SYSTEM AND METHODS |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2671356B1 (fr) | 1991-01-09 | 1993-04-30 | Inst Nat Sante Rech Med | Procede de description des repertoires d'anticorps (ab) et des recepteurs des cellules t (tcr) du systeme immunitaire d'un individu. |
| US6221600B1 (en) * | 1999-10-08 | 2001-04-24 | Board Of Regents, The University Of Texas System | Combinatorial oligonucleotide PCR: a method for rapid, global expression analysis |
| EP2460889B1 (en) * | 2002-10-11 | 2013-11-20 | Erasmus Universiteit Rotterdam | Nucleic acid amplification primers for PCR-based clonality studies of BCL2-IGH rearrangements |
| US8642513B2 (en) * | 2005-09-15 | 2014-02-04 | Crucell Holland B.V. | Method for preparing immunoglobulin libraries |
| WO2008026927A2 (en) * | 2006-08-30 | 2008-03-06 | Academisch Medisch Centrum | Process for displaying t- and b-cell receptor repertoires |
| CA2796822C (en) * | 2010-05-07 | 2021-10-05 | The Board Of Trustees Of The Leland Standford Junior University | Measurement and comparison of immune diversity by high-throughput sequencing |
| EP2625295B1 (en) * | 2010-10-08 | 2019-03-13 | President and Fellows of Harvard College | High-throughput immune sequencing |
-
2012
- 2012-03-02 GB GBGB1203720.6A patent/GB201203720D0/en not_active Ceased
-
2013
- 2013-03-01 US US14/382,142 patent/US9797014B2/en not_active Expired - Fee Related
- 2013-03-01 WO PCT/GB2013/050516 patent/WO2013128204A1/en not_active Ceased
- 2013-03-01 EP EP13709986.7A patent/EP2820153B1/en not_active Not-in-force
- 2013-03-01 JP JP2014559299A patent/JP6513949B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2820153B1 (en) | 2018-12-05 |
| JP2015509724A (ja) | 2015-04-02 |
| WO2013128204A1 (en) | 2013-09-06 |
| US9797014B2 (en) | 2017-10-24 |
| GB201203720D0 (en) | 2012-04-18 |
| US20150031042A1 (en) | 2015-01-29 |
| EP2820153A1 (en) | 2015-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12247248B2 (en) | Methods and kits for labeling cellular molecules | |
| US20200399690A1 (en) | Compositions and methods for selection of nucleic acids | |
| Head et al. | Library construction for next-generation sequencing: overviews and challenges | |
| JP6324962B2 (ja) | 標的ｒｎａ枯渇化組成物を調製するための方法およびキット | |
| JP6513949B2 (ja) | Ｖｄｊ組み換え産物を特定する方法 | |
| JP2009508495A (ja) | ｃＤＮＡライブラリー調製 | |
| KR20210114918A (ko) | 복합체 표면-결합 트랜스포좀 복합체 | |
| JP2018503403A (ja) | 液相におけるライゲーションアッセイ | |
| CN107075731A (zh) | 一种核酸单链环状文库的构建方法和试剂 | |
| KR20170020704A (ko) | 개별 세포 또는 세포 개체군으로부터 핵산을 분석하는 방법 | |
| WO2022021279A1 (zh) | 多种核酸共标记支持物及其制作方法与应用 | |
| JP2018506307A (ja) | 非特異的増幅産物を減少させる為の方法及び組成物 | |
| JP2019514360A (ja) | 超並列シークエンシングのためのｄｎａライブラリーを生成する方法及びキット | |
| CN104531874B (zh) | Egfr基因突变检测方法及试剂盒 | |
| CN116949132A (zh) | 一种构建单细胞测序文库的方法 | |
| EP4010493B1 (en) | Methods for the multiplexed isothermal amplification of nucleic acid sequences | |
| JP2020509747A (ja) | 複数の標的を増幅するためのダイマー回避マルチプレックスポリメラーゼ連鎖反応 | |
| US20220220545A1 (en) | Methods for production and quantification of unique molecular identifier-labeled beads | |
| JP2022548000A (ja) | シーケンシングライブラリーの多重製造方法 | |
| WO2024250155A1 (zh) | 一种构建单细胞测序文库的方法 | |
| WO2025128786A1 (en) | Methods for simultaneous characterization of genome and transcriptome of a single cell | |
| Head et al. | Practical Guide | |
| HK40075118B (en) | Methods for the multiplexed isothermal amplification of nucleic acid sequences | |
| US20180171398A1 (en) | Improvements in and relating to nucleic acid probes and hybridisation methods | |
| JP2005312442A (ja) | マイクロビーズの精製方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150819 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160225 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160225 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161220 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170215 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170619 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171003 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20171214 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180330 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180807 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20181101 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190205 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190319 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190411 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6513949 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |